IDH1 Mutation in Gliomas in Mosul City - Iraq

Abstract

BACKGROUND:IDH1 (isocitrate dehydrogenase 1) mutation might be encounter in the low grade glioma and directs the progression of the tumor to a higher grade.OBJECTIVE:To assess the frequency of IDH1 mutations in gliomas and to correlate the IDH1 positivity with the type and grade of tumors, the age and sex of the patients.MATERIAL AND METHODS:A retro– and prospective case series study. One hundred and nine cases of intracranial gliomas were collected between 2008 and 2014 from Mosul Private Laboratories and Al-Jamboree Teaching Hospitals in Mosul. IDH1 mutations were assessed immunohistochemically using anti-IDH1 R132H mouse monoclonal antibody.RESULTS:IDH1 mutation was perceived in 34.86% of gliomas. In adult gliomas, the secondary glioblastoma and the low-grade astrocytoma had the greatest values of IDH1 positivity (88.88% and 62.5% respectively), followed by oligoastrocytoma/oligodendroglioma (50.0%), and anaplastic astrocytoma (47.36%). The primary glioblastomsa showed 17.64% IDH1 positivity. Males and females expressed the IDH1 equally. While, there was no role of IDH1 in pediatric gliomas.CONCLUSION:IDH1 mutation is commonly present in adult gliomas particularly in low-grade gliomas, and secondary glioblastoma, with equal sex distribution, but it has no role in pediatric gliomas.

<i>IDH1</i> Mutation in Gliomas in Baghdad by Immunohistochemical Study

“…Therefore, there was a statically correlation between adult and pediatric gliomas although IDH1 highly expressed in young and middle age patients. This is in agreement with other related studies [20], [26], [29], [47], [48], [49], [50], which established no role of IDH1 mutation in pediatric gliomas. This explained by the frequency, pathological spectrum and the anatomical location of gliomas in this age group.…”

“…In contrast to the majority of the previous studies [18], [20], [21], [29], [31], [33], [35], [36], [37], [38], [39]. The present study clarified a relatively higher degree of IDH1 expression in primary glioblastoma (26.7%).…”

“…IDH1 mutation has become as a main diagnostic and prognostic biomarker for gliomas [6], [30]. In line with many previous studies, that reported a higher frequency of IDH1 in low grade diffuse astrocytoma, oligodendroglial tumors, anaplastic astrocytoma and secondary glioblastoma in compare with primary glioblastoma and other pathological types [20], [29], [31], [32], [33], [34], [35]. The current study showed highest IDH1 positivity among diffuse astrocytomas (72.72%), oligodendrogliomas (81.8%) and secondary glioblastoma (87.5%), there was significant association between expression of IDH1 and pathological types of gliomas.…”

“…The present study clarified a relatively higher degree of IDH1 expression in primary glioblastoma (26.7%). This may be due to ambiguous presentation, delay diagnosis and treatment of some of low grade gliomas that presented initially as primary glioblastomas [29]. Nobusawa proposed that these primary glioblastomas with IDH1 mutation actually represent secondary glioblastomas with an unusually short clinical presentation [40].…”

“…Determination of IDH1 positivity did by visual semi quantitative assessment of the proportion of the positively staining tumor cells. Cases with equal or more than 10% IDH1 expression considered as positive, while cases with less than 10% cells were negative [9], [29], [30].…”